GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

June 15, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

COVID-19

Interventions

DRUG

GS-441524

Oral GS-441524 capsules

DRUG

Placebo

Placebo capsules

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Leidos Biomedical Research, Inc.

INDUSTRY

collaborator

ICON Government and Public Health Solutions, Inc

UNKNOWN

lead

National Center for Advancing Translational Sciences (NCATS)

NIH

NCT06274853 - GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects | Biotech Hunter | Biotech Hunter